In the field of anticancer drug discovery, Zhang and co-workers developed a series of dual inhibitors targeting both the epidermal growth factor receptor (EGFR) and tumor-associated hCA IX by combining quinazoline-based derivatives with benzenesulfonamide moieties [48]. The gene discussed is EGFR; the disease is neoplasm.